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Materials and Methods  
Plasmids 
In addition to the four expression vectors described in the main body of the article, four expression 
vectors were used in this work for expression in E. coli strains (Suppl. Figure S1a) described as follows: a) 
pET22b-GLA constructed by the insertion of a NdeI-EcoRI DNA fragment encoding the mature form of the 
hGLA with a His-tag and TEV protease cleavage site in pET22b; b) pDAss-GLA, constructed by the insertion 
of a BamHI-HindIII DNA fragment encoding the mature form of the hGLA protein with a His-tag and TEV 
protease cleavage site in parental vector pDAss. pDAss is a pTrc99-derived expression vector containing the 
leader peptide of disulfide isomerase I protein (DsbA) for periplasmic secretion and was kindly provided by 
Juan-Miguel Puertas and Jean-Michel Betton from the Unité de Microbiologie Structurale of the Institut 
Pasteur, Paris; c) pGEX4T2-GLAmut1, derived from pGEX4T2-GLA, was constructed by site-directed 
mutagenesis to optimise codon usage of R392 and R402 of hGLA ORF using Quikchange Lightning site-
directed mutagenesis kit (Stratagene 210518) (Figure S1b). R392 and R402 codons were modified in two 
consecutive mutagenesis steps. Wild type R392 and R402 AGG codon were mutated to CGC and CGT 
codons respectively; d) pGEX4T2-GLAmut2, modified hGLA gene from pGEX4T2-GLAmut1 was subjected 
to a third mutagenesis cycle to eliminate a putative E. coli transcriptional terminator (Nudler and Gottesman, 
2002) since analysis of sequence propensity in the formation of secondary structure using Vector NTI suite 9 
(informax, Invitrogen) revealed that it was energetically favorable (∆G=-2.7Kcal/mol) (Suppl. Figure. S1b). 
Periplasm fractionation in E. coli cell cultures 
Periplasm fractionation in pDAss-GLA transformed E. coli cells was obtained by osmotic stress. 
Treated cells were centrifuged and periplasmic cell fraction was recovered from the supernatant leaving 
concentrated spheroplasts in the pellet (Miot and Betton, 2007). 
 
Results  
Recombinant expression of human GLA ORF in E. coli 
Suppl. Figure S2 shows the detection of the hGLA produced by E. coli BL21(DE3) strain transformed with 
pReceiver-B01-GLA. As it can be seen, the protein was produced under all the assayed conditions although in 
the insoluble cell fraction only. However, when compared with the molecular weight markers, it was observed 
that the molecular weight of the obtained product seemed slightly lower than expected (theoretical molecular 
mass of the recombinant hGLA≈ 49.6 kDa). As seen in Suppl. Figure 1a, this recombinant hGLA contains an 
N-terminal His-tag that can be detected in the insoluble cell fraction of induced cultures indicating that the 
recombinant hGLA is probably C-terminally proteolysed. In addition, an anti-GLA antibody raised against the 
last 100 amino acids of GLA (Santa Cruz Biotechnology, data not shown) could also detect hGLA in the 
insoluble cell fraction indicating that less than 100 amino acids have been proteolysed at the C-terminus. 
Other positive protein bands were also detected which could correspond to either aggregated GLA products or 
proteolysed forms of the His-tagged hGLA.  
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Recombinant production of mature form of hGLA in E. coli 
The complete ORF of hGLA includes its secretion signal, it has been observed that the eukaryotic signal 
peptides are not processed in prokaryotic expression systems, therefore, the secretion signal included in 
hGLA gene was eliminated and the resulting gene was fused to a N-terminal His-tag and Tobacco Etch Virus 
(TEV) protease cleavage site and used in expression experiments either to be expressed in the cytoplasm of 
transformed cells or sent to the periplasm by adding specific secretion signals (pET22b-GLA and pDAss-
GLA respectively in Suppl. Figure S1a).  
 
Rosetta-gami B(DE3) cells were transformed with pET22b-GLA vector and used to produce a N-terminally 
his-tagged mature form of hGLA in shake cultures induced at either 20ºC or 37ºC at different IPTG 
concentrations (Suppl. Figure S3). The Rosetta-gami B(DE3) strain is able to compensate low concentrations 
of certain tRNAs of E. coli and improve recombinant protein translation in addition to providing an oxidizing 
cytoplasm in which protein disulphide bridges can be formed. However, the theoretical 47.8 kDa protein band 
corresponding to the his-tagged hGLA was not detected. In fact, only a specific 25 kDa protein band was 
detected when using anti-GLA antibodies in cultures induced at 20ºC in both soluble and insoluble fractions 
regardless of the IPTG concentration, a protein band which can be barely detected when induction of gene 
expression was performed at 37ºC. When samples were developed with the monoclonal anti His-tag antibody, 
no bands were detected suggesting an N-terminal proteolysis (data not shown). The mature form of hGLA in 
the Rosetta-gami B(DE3) strain seemed to be completely translated since it could be detected by antibodies 
raised against the C-terminal end of the protein but it seems that is degraded to a proteolytically reluctant 
smaller polypeptide of 25 kDa.  
Protein expression experiments were carried out with transformed Rosetta 2(DE3) cells with pDass-GLA to 
test the presence of hGLA in the periplasmic fraction of the cells (Suppl. Figure 4). Specific bands were 
detected in all the assayed conditions although aggregated forms were also observed in positive lanes. A band 
of approximately 40 kDa appeared in all lanes which corresponded to a proteolysed product as observed in the 
preceding experiments. Correspondingly, a protein band displaying slightly lower molecular weight was 
detected exclusively in periplasmic samples as the result of the periplasmic secretion signal peptide 
processing to get into the periplasmic space.  
Samples were also tested against a monoclonal anti-His antibody revealing the presence of macromolecular 
complexes and a specific band of 42 kDa only present in the insoluble cellular fraction, indicating that the N-
terminal end in both soluble and periplasm samples had been removed. Therefore, the mature form of the 
hGLA could be translated and sent to the periplasm although it is degraded at least N-terminally.  
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a) pET22b-GLA cytoplasm 420 aaGLA
b) pDAss-GLA periplasm 415 aaGLA
c) pGEX4T2-GLAmut1 cytoplasm 640 aaGLAGST
d) pGEX4T2-GLAmut2 cytoplasm 640 aaGLAGST
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Suppl. Figure S1 (a) Expression vectors used in recombinant hGLA production assays. 
Expression vectors used in E. coli strains: a) to d). GST: Glutathione S-transferase, 
GLA: hGLA gene. Tobacco Etch Virus protease cleavage site (TEVp) location is marked
by an arrow tip. His-tag is marked by a stripped box. GLA mut1 gene corrects two rare
codons for arginine of the human GLA coding sequence to make it compatible with
the E. coli expression system. GLAmut2 gene corresponds to GLAmut1 coding
sequence with silent mutations to avoid putative transcriptional terminator (b) 
Hairpin configuration of putative E. coli transcriptional terminator in RNA derived
sequence of underlined amino acids in Fig. 1b. Base specific modifications are 
depicted in bold. DNA coding sequence is shown before and after site-directed
mutagenesis to obtain pGEX4T2-mut2. 
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Suppl. Figure S2 Western blot developed with monoclonal antibody against His-
tag of soluble and insoluble fractions of induced BL21(DE3)/pReceiver-B01-GLA 
cultures. Gene expression induction was set at 15°C, 20°C, 25°C or 30°C for 16 h. 
Volumes corresponding to equal OD values were loaded in all the lanes. S and I 
correspond to the soluble and insoluble cell fractions of induced cultures. 
Molecular weight marker standards are indicated in kDa at both blot sides (Dual 
color, BioRad).
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Suppl. Figure S3 Western blot analysis of soluble (S) and insoluble (I) 
cellular fractions of Rosetta-gami B(DE3) cell cultures transformed 
with pET22b-GLA under different IPTG concentrations and induction 
temperatures, developed with polyclonal anti-GLA antibody (Santa 
Cruz Biotechnology). Non induced cell cultures are noted as NC 
lanes. Molecular weight marker standards are indicated in kDa (Dual 
color, BioRad).
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Suppl. Figure S4 Western blot analysis of soluble (S), insoluble (I) and periplasmic
cellular fraction (P) of Rosetta 2(DE3) cell cultures transformed with pDass-GLA 
developed with (a) polyclonal anti-GLA antibody (Sigma). (b) monoclonal anti-his tag 
(GE Healthcare). The unprocessed form of the hGLA is marked by an arrow with 
discontinued line and the secreted form of hGLA is marked by an arrow. Molecular 
weight marker standards are indicated in kDa (Dual color, BioRad).
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Suppl. Figure S5 ( a) Coomassie blue stained SDS-PAGE of soluble and 
insoluble cellular fractions of Rosetta-gami B(DE3) cell cultures 
transformed with pGEX4T2-GLA at different temperatures and IPTG 
concentrations. (b) Western blot analysis of the same samples using a 
polyclonal anti-GLA antibody (Santa Cruz Biotecnology). Molecular 
weight marker standards are indicated in kDa (Dual color, BioRad).
